Clinical Trial

Safety and Immune Response of a Rabies Vaccine With the Essen Schedule and a Two-Dose Booster

Completed Phase 3
View on ClinicalTrials.gov →
Summary
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals. Over the years, the Vero cell rabies vaccine has been recognized by the World Health Organization (WHO) and the European Union, and is widely used globally. Currently, one of the post-exposure prophylaxis (PEP) regimens recommended by the World Health Organization (WHO) is the five-dose "Essen" regimen (1-1-1-1-1), involving one intramuscular dose administered on days 0, 3, 7, 14, and 28 respectively. This clinical trial was to assess the immunogenicity and safety of a freeze-dried human rabies vaccine (Vero Cell) in healthy population for the large-scale developing, and explore the booster vaccination.
Trial Details
NCT Number NCT07672626
Lead Sponsor Jiangsu Province Centers for Disease Control and Prevention
Conditions Vaccine
Enrollment 1,200 participants
Start Date 2022-07-19
Primary Completion 2024-08-26 (estimated)
Study Completion 2024-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-29